NPCE NASDAQ
NeuroPace, Inc.
1W: +1.7%
1M: -7.6%
3M: -15.2%
YTD: -14.4%
1Y: +23.1%
3Y: +116.5%
5Y: -16.7%
$13.02
+0.03 (+0.23%)
After Hours: $13.00 (-0.02, -0.15%)
Weekly Expected Move ±6.9%
$11
$12
$13
$14
$15
Credit Risk of going bust: higher than 54% of companies Debt: 13.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.20 (down 98%), NeuroPace, Inc. would be worth roughly what it owes.
Total debt $69.9M against a stock market value of $445.9M.
Distance to default 4.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $29.5M (short-term plus half of long-term), stock volatility 59.4%; Altman Z -3.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.20 (down 98%), NeuroPace, Inc. would be worth roughly what it owes.
Total debt $69.9M against a stock market value of $445.9M.
Distance to default 4.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $29.5M (short-term plus half of long-term), stock volatility 59.4%; Altman Z -3.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-08-11
Earliest Filing
2025-02-14
Latest Filing
partner: 3
investor: 1
Counterparties (Filed by NPCE)
4 relationshipsCompanies named in NPCE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| KCK Ltd. | — | investor | Target of stock repurchase agreement where NeuroPace agreed to buy back all shares held by KCK. | 2025-02-14 | View |
| Rapport Therapeutics, Inc. | RAPP | partner | NeuroPace will provide site data and monitoring capabilities for Rapport's Phase 2a trial of their RAP compound. | 2023-12-04 | View |
| DIXI Medical USA Corp. | — | partner | Exclusive distribution agreement for DIXI Medical's SEEG electrodes in the United States | 2022-08-11 | View |
| DIXI Medical | — | partner | European parent company of DIXI Medical USA Corp., supplier of SEEG electrodes | 2022-08-11 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-07-28 | Regulation FD; Exhibits | View | |
| 2026-06-08 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-24 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-06-12 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-04 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of | Agreement | View |
| 2025-05-27 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-04-02 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-03-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-20 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-02-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-14 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-01-28 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-01-15 | Regulation FD Disclosure | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR